ROBOSENSE
22.8.2019 16:57:11 CEST | Business Wire | Press release
RoboSense, the leading supplier of LiDAR perception system solutions, and Aidrivers, the UK's leading provider of autonomous mobility solutions for industrial applications announced today a partnership in system integration. Aidrivers will integrate RoboSense Smart LiDAR Sensor System into their own Autonomous Driving Systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005468/en/
Aidrivers is delivering a fully autonomous natural navigation system that meets industrial safety standards to seaports, particularly for horizontal transportation, aimed for improving operation efficiency and leading the way in industrial autonomous mobility automation. Their solution can work under all harsh weather conditions by achieving true 3D mapping and localization for precision positioning and situation cognisance and they are using RoboSense 3D LiDAR sensor technology, which collects stable and reliable environment information at near and far distance and under different weather conditions.
“ The performance of RoboSense 3D LiDAR products in harsh weather condition is impressive. We have been testing trailer vehicles under heavy rain and harsh weather conditions and our precision positioning system based on true 3D mapping and localization systems provides accurate localization result. The point cloud data quality in rainy days is excellent and outperforming state of the art.” Aidrivers founder and CEO Dr. Rafiq Swash said, “Aidrivers is dedicated to providing safer, reliable and high-quality Ai enabled autonomous mobility solutions for industrial transportation, and the partnership with RoboSense will give a great confidence to our end users that we are providing autonomous solutions which overcome current challenges of industrial horizontal transportation. Our Ai enabled autonomous solutions are now catering to more industrial transportation industries for both indoor and outdoor in complex environment and weather conditions.”
As one of the pioneer companies to commercialize autonomous driving technology in UK, Aidrivers has been favored by industry giants in the field of autonomous port automation. Aidrivers is deploying a fleet of autonomous prime movers for the world’s leading and busiest port terminals. Aidrivers and SANY have recently partnered to deliver autonomous electric vehicles, specifically industrial horizontal transport solutions, for the Chinese market.
Video about Aidrivers and SANY’s vehicle : https://twitter.com/aidriversltd/status/1141257250629177344?s=20
In these projects, the AI enabled autonomous mobility solutions provided by Aidrivers use RoboSense's 3D LiDARs to collect rich and reliable environment perception data, conduct real-time accurate 3D object detection and tracking. Aidrivers is leading the situation cognisance with AI enabled data fusion to deliver a safer and reliable autonomous driving solutions for complex trailer vehicles under harsh weather.
“Aidrivers is driving the commercialization of autonomous driving technology for industrial transportation on a global scale. RoboSense is very pleased to collaborate with Aidrivers to build safer and robust autonomous driving solutions for major port terminals, and push for the commercialization of this technology.” RoboSense Co-founder and COO, Mark said, “Through in-depth cooperation with Aidrivers, RoboSense will continue to explore and understand the needs of industrial automation, and together with our partners, we will optimize and launch more practical LiDAR perception systems from the application perspective. ”
RoboSense's LiDAR sensors, AI Perception Algorithms and Smart LiDAR Sensor System are widely used in various types of autonomous driving scenarios. Currently, RoboSenses partners covers the world's major autonomous driving technology companies, automotive OEMs, and Tier 1 suppliers. RoboSense has always striven to optimize product performance and reliability to help autonomous driving vehicles to better cope with harsh environments and extreme conditions.
For more information please visit https://aidrivers.ai/ and https://www.robosense.ai/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190822005468/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom